SAHM Strongly Recommends Human Papillomavirus Vaccination For 9- To 26-Year-Old Males

On May 28, 2010, the Advisory Committee on Immunization Practices (ACIP) published its guidance for use of the quadrivalent HPV vaccine in males…

Women Who Consume Large Amounts Of Tea Have Increased Risk Of Rheumatoid Arthritis

Women who drink tea have an increased risk of developing Rheumatoid Arthritis (RA) compared with those who drink none (p=0.04), according to results presented at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Further results from the same study showed no correlation between the amount of coffee consumption and [...]

FDA Okays New First-Line Therapy for Rare Leukemia

WASHINGTON (MedPage Today) — The FDA has approved nilotinib (Tasigna) as first-line therapy for the rare blood and bone marrow disorder Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML).

Washington Week: Senate Passes SGR Fix; FDA Panel Backs One Drug, Nixes Another

WASHINGTON (MedPage Today) — The U.S. Senate voted to delay a steep pay cut for doctors, but not before CMS began processing claims at the lower rate, an FDA panel approved a new morning-after pill and voted against “female Viagra”, and the agency fined the Red Cross for blood safety violations.

FDA Okays New First-Line Therapy for Rare Leukemia

WASHINGTON (MedPage Today) — The FDA has approved nilotinib (Tasigna) as first-line therapy for the rare blood and bone marrow disorder Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML).

Washington Week: Senate Passes SGR Fix; FDA Panel Backs One Drug, Nixes Another

WASHINGTON (MedPage Today) — The U.S. Senate voted to delay a steep pay cut for doctors, but not before CMS began processing claims at the lower rate, an FDA panel approved a new morning-after pill and voted against “female Viagra”, and the agency fined the Red Cross for blood safety violations.

New phase I/IIa clinical trial of AR-42 for blood cancer at OSUCCC-James

For the second time within a year, an experimental drug invented by cancer researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) is being tested on patients in a clinical trial.

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of [...]

Neupro® (Rotigotine Transdermal System) Significantly Improved Wellbeing And Daily Activities Impaired Due To Limb Pain

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina…

FDA Advisory Committee Unanimously Recommends Approval Of HRA Pharma’s Ulipristal Acetate For Emergency Contraception

HRA Pharma announced that the U.S. Food and Drug Administration’s (FDA) Advisory Committee for Reproductive Health Drugs voted 11 to 0 that the company’s application provided sufficient information to conclude that ulipristal acetate is effective and safe for use as an emergency contraceptive…